Injectable GLP-1 medications are administered via a small subcutaneous injection, typically once weekly (semaglutide, tirzepatide) or once daily (liraglutide)
Our approach is built on science, safety, and individualization
Patients should be counseled that gastrointestinal symptoms usually improve within 48 weeks of reaching a stable dose
2 and 3, Supplementary Table 3)
No surprise pharmacy invoices
Importantly, many peptide programs historically failed not because they were scientifically unsound, but because they were misaligned with regulatory frameworks, economic realities, or the prevailing standards of evidence at the time of evaluation